Gamida Cell Ltd. - GMDA STOCK NEWS

Gamida Cell Ltd. (Nasdaq: GMDA) will host a conference call on March 9, 2021, at 8:30 a.m. ET to discuss its full year 2020 financial results and company updates. Interested parties can access the live audio webcast through the 'Investors & Media' section of Gamida Cell's website. Participants can join the call by dialing 866-930-5560 (domestic) or 409-216-0605 (international), referencing conference ID 1996281. A replay will be available approximately two hours post-event for 30 days.

Gamida Cell Ltd. (Nasdaq: GMDA) announced the presentation of results from its Phase 3 clinical trial of omidubicel at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2021). The presentation is scheduled for March 15, 2021, at 3:24 p.m. CET. Omidubicel, an advanced cell therapy for blood cancers, has shown significant results in prior studies and plans to submit a Biologics License Application (BLA) to the FDA in H2 2021. The company aims to redefine standards of care in hematologic malignancies.

Gamida Cell Ltd. (Nasdaq: GMDA) has announced the sale of $75 million in 5.875% exchangeable senior notes due in 2026 to funds managed by Highbridge Capital Management. The proceeds, along with previous funding, will support operational liquidity into H2 2022, focusing on manufacturing and regulatory activities for omidubicel and GDA-201. CEO Julian Adams emphasized that this financing strengthens the company's financial position, allowing for advancement in clinical development and regulatory submissions for omidubicel, which has shown promising Phase 3 results.

Gamida Cell Ltd. (Nasdaq: GMDA) announced Phase 3 clinical study results of omidubicel for high-risk hematologic malignancies, presented at the TCT Meetings. The study showed that omidubicel led to faster hematopoietic recovery, fewer infections, and reduced hospitalization days compared to standard umbilical cord blood transplants. The median time to neutrophil engraftment was 12 days versus 22 days for the comparator (p<0.001). Gamida Cell plans to submit a Biologics License Application to the FDA in H2 2021, potentially establishing omidubicel as a new standard of care.

Gamida Cell Ltd. (Nasdaq: GMDA) announced the presentation of full Phase 3 trial results for omidubicel at the upcoming TCT Meetings, scheduled from February 8–12, 2021. This randomized, international study assessed omidubicel's efficacy and safety compared to standard umbilical cord blood transplants in patients with blood cancers undergoing transplant. Previous data indicated successful primary and secondary endpoints, notably improved engraftment timelines. The presentation is led by Dr. Mitchell E. Horwitz on February 9, 2021, and the company plans to file a biologics license application with the FDA later in 2021.

Gamida Cell Ltd. (Nasdaq: GMDA), a leading cell therapy company, will participate in two investor conferences in January 2021. The H.C. Wainwright Bioconnect 2021 Conference is scheduled for January 11-14, with its presentation available for on-demand viewing starting January 11 at 6:00 a.m. ET. Additionally, at the 15th Annual Stern IR Corporate Access Event, the company will provide its presentation on January 11 at 7:00 a.m. ET, alongside one-on-one meetings from January 11-14. Webcasts will be accessible on Gamida Cell's website for 14 days post-event.

Gamida Cell Ltd. (Nasdaq: GMDA) has completed its public offering, closing on December 21, 2020. The offering included 9,343,750 ordinary shares at $8.00 per share, yielding gross proceeds of approximately $74.75 million before expenses. This total reflects the full exercise of underwriters' options, allowing for an additional 1,218,750 shares. Piper Sandler & Co., Evercore Group, and JMP Securities managed the offering. The securities were registered under Form F-3, declared effective on November 27, 2019.

Gamida Cell Ltd. (Nasdaq: GMDA) has been selected for inclusion in the NASDAQ Biotechnology Index, effective December 21, 2020. This index tracks the performance of biotechnology and pharmaceutical securities listed on NASDAQ, which must meet minimum market value and share volume criteria. Inclusion in the index may enhance GMDA's visibility and attract more investment as it forms the basis for various Exchange-Traded Funds (ETFs). Gamida Cell focuses on advanced cell therapies aimed at treating blood cancers and serious hematologic diseases.

Gamida Cell Ltd. (Nasdaq: GMDA) announced a public offering of 8,125,000 ordinary shares priced at $8.00 each, raising $65.0 million in gross proceeds. The offering includes an option for underwriters to purchase an additional 1,218,750 shares. Proceeds will fund the commercial launch of omidubicel, continue clinical development of candidates like GDA-201, and expand manufacturing capabilities. The closing is expected on or about December 21, 2020, pending customary conditions.